Evidence map›Paper›PMID 22932714›Full record

Trial reportLancet (London, England)2012

Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial.

Raul G Nogueira, Helmi L Lutsep, Rishi Gupta, Tudor G Jovin, Gregory W Albers, Gary A Walker, David S Liebeskind, Wade S Smith, TREVO 2 Trialists

Erratum issued 4 registry-linked trialsAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 403 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
403citing papers in PubMed, 14 pooled it
111.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01270867 nacompletednot on this map

Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)

TypeinterventionalSponsorStryker NeurovascularRan2011 to 2012Enrolled178ConditionsIschemic StrokeArmsMechanical Thrombectomy
NCT02135926 naterminatednot on this mapstarted 2014, after this paper: background citation

Comparison of Thrombectomy and Standard Care for Ischemic Stroke in Patients Ineligibility for Tissue Plasminogen Activator Treatment

TypeinterventionalSponsorUniversity Hospital HeidelbergRan2014 to 2017Enrolled4ConditionsIschemic StrokeArmsThrombectomy, Best medical care
NCT02441556 nacompletednot on this mapstarted 2015, after this paper: background citation

Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment

TypeinterventionalSponsorXinfeng LiuRan2015 to 2017Enrolled131ConditionsStroke Due to Basilar Artery Occlusion, Acute Cerebrovascular AccidentsArmsendovascular treatment, standard medical therapy
NCT02818868 completednot on this mapstarted 2016, after this paper: background citation

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

TypeobservationalSponsorHyogo Medical UniversityRan2016 to 2018Enrolled700ConditionsIschemic StrokeArmsapixisaban
3 · Its place in the literature

Who cites it

403 citing papers in PubMed, 14 syntheses or guidelines pooled it, 1,108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. First-line contact aspiration vs stent-retriever thrombectomy in acute ischemic stroke patients with large-artery occlusion in the anterior circulation: Systematic review and meta-analysis.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2019
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2016
    Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. One-year single-center experience with the Aperio thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Trial
  19. Trial
  20. Trial

343 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Raul G NogueiraDepartment of Neurology, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA 30303, USA. raul.g.nogueira@emory.edu
Helmi L Lutsep
Rishi Gupta
Tudor G Jovin
Gregory W Albers
Gary A Walker
David S Liebeskind
Wade S Smith
TREVO 2 Trialists
Emory University · USGrady Memorial Hospital · USOregon Health & Science University · USStanford Medicine · USStryker (United States) · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Pittsburgh Medical Center · US

Funding

Modeling of Collateral Perfusion in the Ischemic BrainK24NS072272 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIEBESKIND, DAVID SIGMUND · 2011 to 2015
$939k
NINDS NIH HHS K24 NS072272
6 · The paper itself

Abstract

backgroundPresent mechanical devices are unable to achieve recanalisation in up to 20-40% of large vessel occlusion strokes. We compared efficacy and safety of the Trevo Retriever, a new stent-like device, with its US Food and Drug Administration-cleared predecessor, the Merci Retriever.

methodsIn this open-label randomised controlled trial, we recruited patients at 26 sites in the USA and one in Spain. We included adults aged 18-85 years with angiographically confirmed large vessel occlusion strokes and US National Institutes of Health Stroke Scale (NIHSS) scores of 8-29 within 8 h of symptom onset. We randomly assigned patients (1:1) with sequentially numbered sealed envelopes to thrombectomy with Trevo or Merci devices. Randomisation was stratified by age (≤68 years vs 69-85 years) and NIHSS scores (≤18 vs 19-29) with alternating blocks of various sizes. The primary efficacy endpoint, assessed by an unmasked core laboratory, was thrombolysis in cerebral infarction (TICI) scores of 2 or greater reperfusion with the assigned device alone. The primary safety endpoint was a composite of procedure-related adverse events. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01270867.

findingsBetween Feb 3, 2011, and Dec 1, 2011, we randomly assigned 88 patients to the Trevo Retriever group and 90 patients to Merci Retriever group. 76 (86%) patients in the Trevo group and 54 (60%) in the Merci group met the primary endpoint after the assigned device was used (odds ratio 4·22, 95% CI 1·92-9·69; p(superiority)<0·0001). Incidence of the primary safety endpoint did not differ between groups (13 [15%] patients in the Trevo group vs 21 [23%] in the Merci group; p=0·1826).

interpretationPatients who have had large vessel occlusion strokes but are ineligible for (or refractory to) intravenous tissue plasminogen activator should be treated with the Trevo Retriever in preference to the Merci Retriever.

fundingStryker Neurovascular.

Indexed as

AgedAged, 80 and overBrain IschemiaCerebral AngiographyFemaleHumansMaleStrokeThrombectomy

Identifiers

PMID22932714
PMCPMC4176618
OpenAlexW2134066226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.